Caroline Pirritt

Publications by Year

Research Areas

Growth Hormone and Insulin-like Growth Factors, PI3K/AKT/mTOR signaling in cancer, Metabolism, Diabetes, and Cancer, Cancer, Hypoxia, and Metabolism, Lung Cancer Treatments and Mutations

Most-Cited Works

• → Discovery of OSI-906: A Selective and Orally Efficacious Dual Inhibitor of the IGF-1 Receptor and Insulin Receptor(2009)307 cited
• → A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo(2007)147 cited
• In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)(2007)
• Preclinical characterization of OSI-906: A novel IGF-1R kinase inhibitor in clinical trials(2007)
• → Antitumor efficacy of OSI-930 and the molecular targeted agent erlotinib in preclinical xenograft models(2008)3 cited
• → 546 POSTER Efficacy of a selective small molecule IGF-IR kinase inhibitor in mouse xenografts models as a single agent and in combination with erlotinib(2006)
• → Supplementary Material from A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling <i>in vitro</i> and inhibits insulin-like growth factor-I receptor–dependent tumor growth <i>in vivo</i>(2023)
• → Data from A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling <i>in vitro</i> and inhibits insulin-like growth factor-I receptor–dependent tumor growth <i>in vivo</i>(2023)
• Abstract #1741: Combination treatment strategy of an IGF-1R kinase inhibitor, OSI-906, in models of progressive disease following initial response to EGFR tyrosine kinase inhibitor therapy(2009)